000 01350 a2200361 4500
005 20250515060544.0
264 0 _c20070515
008 200705s 0 0 eng d
022 _a0269-8811
024 7 _a10.1177/0269881107076418
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aKerwin, Robert
245 0 0 _aThe House of Commons Health Committee: 'The Influence of the Pharmaceutical Industry'. Too much too late?
_h[electronic resource]
260 _bJournal of psychopharmacology (Oxford, England)
_cMar 2007
300 _a131-3 p.
_bdigital
500 _aPublication Type: Editorial
650 0 4 _aAdvertising
_xethics
650 0 4 _aAntipsychotic Agents
_xeconomics
650 0 4 _aClinical Trials as Topic
_xlegislation & jurisprudence
650 0 4 _aDrug Industry
_xeconomics
650 0 4 _aHumans
650 0 4 _aLobbying
650 0 4 _aMarketing
_xeconomics
650 0 4 _aPatents as Topic
_xlegislation & jurisprudence
650 0 4 _aPersuasive Communication
650 0 4 _aPolitics
650 0 4 _aPractice Guidelines as Topic
_xstandards
650 0 4 _aPractice Patterns, Physicians'
650 0 4 _aRegistries
650 0 4 _aUnited Kingdom
773 0 _tJournal of psychopharmacology (Oxford, England)
_gvol. 21
_gno. 2
_gp. 131-3
856 4 0 _uhttps://doi.org/10.1177/0269881107076418
_zAvailable from publisher's website
999 _c16886760
_d16886760